Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? (Q38664735)

5 September 2017

1 reference

title

Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? (English)

1 reference

5 September 2017

acute myeloid leukemia

1 reference

Maximilian Stahl

1

1 reference

5 September 2017

Benjamin Y Lu

series ordinal

2

1 reference

5 September 2017

Tae Kon Kim

series ordinal

3

1 reference

5 September 2017

Amer M Zeidan

series ordinal

4

1 reference

5 September 2017

29 June 2017

1 reference

5 September 2017

1 reference

5 September 2017

12

1 reference

5 September 2017

413-447

1 reference

5 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-017-0503-8

5 September 2017

0 references

cites work

Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Selecting initial treatment of acute myeloid leukaemia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

21 January 2018

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Genomic Classification and Prognosis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Emerging therapeutic drugs for AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Implications of NRAS mutations in AML: a study of 2502 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Shared and separate functions of polo-like kinases and aurora kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Plk1: unexpected roles in DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Polo-like kinase inhibitors in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Acute graft-versus-host disease: more than just alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Epigenetics in Cancer: A Hematological Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

EZH2 in normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Emerging biological therapies for the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

hDOT1L links histone methylation to leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

MLL translocations, histone modifications and leukaemia stem-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeting cellular metabolism to improve cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Otto Warburg's contributions to current concepts of cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

IDH mutations in cancer and progress toward development of targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunotherapy for acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunotherapy for Acute Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Molecules and mechanisms of the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Novel perspectives on dendritic cell-based immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Vaccines as consolidation therapy for myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Role of cytokines in the treatment of acute leukemias: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Circulating CD33 and its clinical value in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Toxicities of chimeric antigen receptor T cells: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Utilizing chimeric antigen receptors to direct natural killer cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Advantages and applications of CAR-expressing natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The origin and evolution of mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Human tumor cells killed by anthracyclines induce a tumor-specific immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Impaired von Willebrand factor adhesion and platelet response in thrombospondin-2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0503-8

Augmenting antitumor immune responses with epigenetic modifying agents

21 January 2018

1 reference

12 December 2020

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

1 reference

12 December 2020

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

1 reference

12 December 2020

A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Functional expression of chimeric receptor genes in human T cells

1 reference

12 December 2020

Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia

1 reference

12 December 2020

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

12 December 2020

Biochemistry of azacitidine: a review.

1 reference

12 December 2020

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

12 December 2020

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

1 reference

12 December 2020

Phase specificity of 5-azacytidine against mammalian cells in tissue culture

1 reference

12 December 2020

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia

1 reference

12 December 2020

[Origin of cancer cells]

1 reference

12 December 2020

Ariad suspends ponatinib sales

1 reference

12 December 2020

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

1 reference

12 December 2020

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells

1 reference

12 December 2020

Targeting epigenetic programs in MLL-rearranged leukemias

1 reference

12 December 2020

Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines

1 reference

12 December 2020

Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia

1 reference

12 December 2020

New drugs in acute myeloid leukemia

1 reference

12 December 2020

Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid

1 reference

12 December 2020

Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1

1 reference

12 December 2020

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

1 reference

12 December 2020

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes

1 reference

12 December 2020

Roads Diverge--A Robert Frost View of Leukemia Development

1 reference

12 December 2020

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia

1 reference

12 December 2020

Targeting the Warburg effect for leukemia therapy: Magnitude matters

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

DARTs take aim at BiTEs

1 reference

12 December 2020

Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy

1 reference

12 December 2020

10.1007/S11523-017-0503-8

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference